Navigation Links
Verenium Announces Debt Repurchase
Date:7/28/2011

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Verenium Corporation (NASDAQ: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that it repurchased approximately $5.2 million in principal amount of its 5.5% Notes and approximately $3 million in principal amount of 9% Notes.  

"We are very pleased to have taken another important step toward creating a capital structure that is appropriate to support the continued growth and success of the Company," said Jeffrey Black, Senior Vice President and Chief Financial Officer at Verenium.  

In total, the Company repurchased approximately $8.2 million in principal amount of its 5.5% and 9% Notes, leaving an aggregate of $36 million in principal amount of 5.5% and 9% Notes outstanding. To effect this repurchase, the Company paid a total of $7.7 million in cash to a single institutional investor, excluding accrued interest, as of the closing date.

About Verenium

Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actua
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Announces Signing of Lease for New Office and Lab Space
2. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
3. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
4. Verenium to Present at Upcoming Conferences
5. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
6. Verenium to Present at MDB Capital Groups Bright Lights Conference
7. Verenium Announces Debt Repurchase
8. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
9. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
10. Verenium to Present at Jefferies 11th Global Clean Technology Conference
11. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... CITY , Nov. 18, 2014  Great Basin Scientific, ... today announced that the management will host a conference call ... and development programs on Thursday, Nov. 20, at 4:30 pm ... we have made since the Company,s recent IPO and would ... Great Basin,s management," said Ryan Ashton , President and ...
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today the formation of a ... guidance to the Company as it advances the ... for the treatment of cutaneous T-cell lymphoma (CTCL), ...
(Date:11/15/2014)... Collaborative Consulting, a privately held, employee-based ... of the Boston Globe’s “Top Places to Work 2014”. ... Massachusetts to receive the honor. , The Boston Globe’s ... of their most valuable resource: the people who work ... are based on an array of criteria, including the ...
(Date:11/15/2014)... November 14, 2014 The ... announced today that the society’s Governing Board has ... Edwards Lifesciences chief scientific officer and Dr. Charles ... officer, Abbott Vascular. Mr. Rowe and Dr. ... device development experts. , Dr. Nabil Dib, ...
Breaking Biology Technology:Great Basin Scientific Announces Conference Call to Provide Update on Corporate Progress 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2International Society for Cardiovascular Translational Research Governing Board Adds Medical Industry Leaders 2
... Group in North America with this Elevated Partner ... ... an Oracle System,Integrator, today announced it has achieved Oracle Certified Advantage,Partner status ... the highest level in the Oracle PartnerNetwork -- BIAS had,to demonstrate superior ...
... for the Long-Term Care Channel, BASKING ... wholly owned subsidiary of Millennium Biotechnologies,Group, Inc. ... the initial,$200,000.00 monthly shipment from Millennium Biotechnologies, ... the previously announced $20,000,000,Five- year exclusive Purchase ...
... Life Sciences R&D to ... Ensure Continued Growth, ... Authority (EDA) announced today that Tris Pharma, Inc. will,expand its ... bonds issued under the state,s Edison Innovation,Fund. Representatives from the ...
Cached Biology Technology:BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 2BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 3Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 3Edison Innovation Fund Helps Tris Pharma Expand 2Edison Innovation Fund Helps Tris Pharma Expand 3
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/5/2014)... RENO – Kelly Redmond has dedicated his career ... knowledge to a general audience. , As deputy ... Climate Center at Nevada,s Desert Research Institute, Redmond ... the management, application and dissemination of climate data ... Annual Fall Meeting in San Francisco on December ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... position is a determinant of antiretroviral treatment effectiveness during ... even among subjects with high rates of drug adherence, ... issue of the Journal of Psychosomatic Research. The ... Harvard School of Public Health (HSPH), Massachusetts General Hospital, ...
... of rotten meat on the premises of a wholesaler in ... grocery stores everywhere is not to be underestimated, the importance ... reliable measurement methods that enable large numbers of samples to ... place in order to make comprehensive monitoring a reality. In ...
... of the GSF National Research Center for Environment ... Centres) the group is continuing to search for cellular ... a prion infection. In collaboration with colleagues from the ... the group used micro-array technologies micro-arrays are ...
Cached Biology News:Socioeconomic position associated with effectiveness of HIV drugs 2New method reveals substances on surfaces of any kind 2Prions and retroviruses -- an unholy alliance? 2
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Agarose II (Low Melt)...
...
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
Biology Products: